Sichuan Biokin Pharmaceutical Co., Ltd.SSE: 688506

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in the Priority Review Program for Treatment of EGFR-TKI-Resistant, EGFR-Mutant Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688506 · · 2 pages · Chinese

Summary by 6ix AI

Yizekang is a first-in-class dual antibody drug that has been recognized for its innovative treatment approach. The company emphasizes the importance of this inclusion for expediting the drug's approval process. Investors are advised to remain cautious due to the inherent risks associated with pharmaceutical development.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/688506sichuan-biokin-pharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-the-inclusion-of-yizekang-izalontamab-brengitecan-bl-b01d1iza-bren-in-the-priority-review-program-for-treatment-of-egfr-tki-resistant-egfr-mutant-locally-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer

Release

Announcement on Voluntary Disclosure of the Inclusion of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in the Priority Review Program for Treatment of EGFR-TKI-Resistant, EGFR-Mutant Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Sichuan Biokin Pharmaceutical

Later from Sichuan Biokin Pharmaceutical

All Sichuan Biokin Pharmaceutical news releases